Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 5, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Stomach Cancer, Adenocarcinoma

Interventions

DRUG

Durvalumab

Durvalumab will be administered at 1500mg every 4 weeks from cycles 1 day 1.

DRUG

Savolitinib

Savoritinib 600mg will be administered orally a day for 28 days as one cycle.

Trial Locations (1)

RECRUITING

Samsung Medical Center, Seoul

All Listed Sponsors

lead

Jeeyun Lee

OTHER